Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Dianthus Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $530.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 41.95% year-over-year to $530.9 million; the TTM figure through Dec 2025 stood at $1.8 billion (up 20.5% YoY), while the FY2025 annual figure was $530.9 million, up 41.95% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $530.9 million, down from $577.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $577.4 million in Q3 2025, with the low at $78.6 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $200.3 million (2021), against an average of $258.7 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 57.07% in 2023, then surged 369.19% in 2024.
• Dianthus Therapeutics' Liabilities and Shareholders Equity stood at $189.9 million in 2021, then slumped by 56.24% to $83.1 million in 2022, then jumped by 115.86% to $179.4 million in 2023, then soared by 108.47% to $374.0 million in 2024, then jumped by 41.95% to $530.9 million in 2025.
• Business Quant data shows DNTH's Liabilities and Shareholders Equity at $530.9 million in Q4 2025, $577.4 million in Q3 2025, and $326.1 million in Q2 2025.